Applied DNA Sciences, Inc. (APDN)
NASDAQ: APDN · Real-Time Price · USD
0.157
-0.005 (-2.91%)
At close: Feb 21, 2025, 4:00 PM
0.159
+0.002 (1.53%)
After-hours: Feb 21, 2025, 7:54 PM EST
Applied DNA Sciences Revenue
Applied DNA Sciences had revenue of $1.20M in the quarter ending December 31, 2024, with 34.28% growth. This brings the company's revenue in the last twelve months to $3.74M, down -58.46% year-over-year. In the fiscal year ending September 30, 2024, Applied DNA Sciences had annual revenue of $3.43M, down -74.33%.
Revenue (ttm)
$3.74M
Revenue Growth
-58.46%
P/S Ratio
0.49
Revenue / Employee
$77,852
Employees
48
Market Cap
8.66M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 3.43M | -9.94M | -74.33% |
Sep 30, 2023 | 13.37M | -4.80M | -26.43% |
Sep 30, 2022 | 18.17M | 9.14M | 101.25% |
Sep 30, 2021 | 9.03M | 7.10M | 367.40% |
Sep 30, 2020 | 1.93M | -3.46M | -64.16% |
Sep 30, 2019 | Pro | Pro | Pro |
Sep 30, 2018 | Pro | Pro | Pro |
Sep 30, 2017 | Pro | Pro | Pro |
Sep 30, 2016 | Pro | Pro | Pro |
Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
APDN News
- 8 days ago - Applied DNA Sciences, Inc. (APDN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress - Accesswire
- 10 days ago - Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025 - Accesswire
- 11 days ago - Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14 - Accesswire
- 6 weeks ago - Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates - Accesswire
- 6 weeks ago - Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter - Accesswire
- 2 months ago - Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA - Accesswire
- 2 months ago - Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines - Accesswire